Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Drug Delivery"
DOI: 10.1080/10717544.2017.1333170
Abstract: Abstract A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG2000-DSPE were incorporated into normal niosomes (NS) via a… read more here.
Keywords: antibody; cd123; anti cd123; daunorubicin ... See more keywords
Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Nanomedicine"
DOI: 10.2147/ijn.s233395
Abstract: Introduction The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increase risk of transformation to acute myeloid leukemia (AML). Daunorubicin (DNR) is an indispensable drug for… read more here.
Keywords: dnr cdte; anti cd123; cdte cd123; cd123 ... See more keywords
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2017.187385
Abstract: Patients with acute myeloid leukemia (AML) often relapse after initial therapy because of persistence of leukemic stem cells that frequently express the IL-3 receptor alpha chain CD123. Natural killer (NK) cell-based therapeutic strategies for AML… read more here.
Keywords: cell; antibody; cd16; anti cd123 ... See more keywords